Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
14.50
+0.24 (1.68%)
Apr 14, 2026, 9:53 AM EDT - Market open
Intellia Therapeutics Revenue
In the year 2025, Intellia Therapeutics had annual revenue of $67.67M with 16.92% growth. Intellia Therapeutics had revenue of $23.02M in the quarter ending December 31, 2025, with 78.79% growth.
Revenue (ttm)
$67.67M
Revenue Growth
+16.92%
P/S Ratio
24.89
Revenue / Employee
$179,499
Employees
377
Market Cap
1.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.67M | 9.79M | 16.92% |
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | 43.10M | 12.67M | 41.63% |
| Dec 31, 2018 | 30.43M | 4.32M | 16.53% |
| Dec 31, 2017 | 26.12M | 9.64M | 58.49% |
| Dec 31, 2016 | 16.48M | 10.44M | 172.65% |
| Dec 31, 2015 | 6.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Ardelyx | 407.32M |
| Immunocore Holdings | 400.02M |
| Iovance Biotherapeutics | 263.50M |
| Nurix Therapeutics | 71.78M |
| Viridian Therapeutics | 70.85M |
| Vir Biotechnology | 68.56M |
| Nuvation Bio | 62.90M |
NTLA News
- 10 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026 - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial - Benzinga
- 6 weeks ago - US FDA lifts clinical hold on Intellia's heart disease gene therapy trial - Reuters
- 6 weeks ago - Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - GlobeNewsWire
- 6 weeks ago - Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - GlobeNewsWire
- 7 weeks ago - Intellia Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates - GlobeNewsWire